Key result
TCAR had 0% 30-day stroke, TIA, MI, or death, and after matching showed no significant difference vs CEA in mortality, composite events, or restenosis.
Why the study?
Does transcarotid artery revascularization (TCAR) provide comparable perioperative safety, long-term neurologic and cardiovascular outcomes, and durability compared to carotid endarterectomy (CEA) in patients with asymptomatic carotid artery stenosis?
Cohort (n=889)
Yes
Does transcarotid artery revascularization (TCAR) provide comparable perioperative safety, long-term neurologic and cardiovascular outcomes, and durability compared to carotid endarterectomy (CEA) in patients with asymptomatic carotid artery stenosis?
In patients with asymptomatic carotid artery stenosis, TCAR demonstrated zero 30-day major adverse events and comparable 4-year propensity-matched neurologic, mortality, and durability outcomes to CEA, supporting its use when CEA is less suitable.
Answers are grounded in this paper and cite their sources.
TCAR was associated with zero perioperative events and similar matched long-term outcomes to CEA; leaves open randomized confirmation of equivalence.
OBJECTIVE: Transcarotid artery revascularization (TCAR) represents an alternative to carotid endarterectomy (CEA) for high-grade carotid artery stenosis treatment. We compared perioperative safety, long-term neurologic and cardiovascular outcomes, and durability after TCAR and CEA across three stroke centers. DESIGN: Retrospective cohort study. METHODS: We analyzed CEA and TCAR procedures for asymptomatic carotid artery stenosis from January 2017 through February 2026 across three institutions. One-to-one nearest-neighbor propensity score matching was performed without replacement. Thirty-day outcomes were compared using the exact McNemar test. Long-term outcomes were evaluated using Cox regression with robust variance estimates. Fine-Gray regression was used to treat death as a competing event for nonfatal outcomes. RESULTS: The final cohort included 889 procedures, 750 CEAs and 139 TCARs. Matching yielded 136 balanced pairs. No ipsilateral stroke, transient ischemic attack (TIA), myocardial infarction (MI), or death occurred within 30 days after TCAR, and no 30-day outcome differed significantly between matched groups. In adjusted analyses of the full cohort, TCAR was associated with mortality (adjusted hazard ratio [aHR], 1.57; 95% confidence interval [CI], 1.07-2.31), stroke or death (aHR, 1.64; 95% CI, 1.13-2.36), and the composite of TIA, stroke, MI, or death (aHR, 1.57; 95% CI, 1.11-2.24). After matching, these associations did not reach statistical significance. Median follow-up in the matched cohort was 4.0 years. Long-term neurologic outcomes also did not differ significantly. Restenosis did not differ significantly (subdistribution HR, 1.43; 95% CI, 0.62-3.30; P = 0.399), and one reintervention occurred in each matched group. CONCLUSION: Among selected asymptomatic patients, TCAR had low perioperative event rates. After matching, no significant differences from CEA were detected in long-term neurologic outcomes, mortality, composite outcomes, restenosis, or reintervention, while late MI remained higher after TCAR. These findings support TCAR as an attractive revascularization option when CEA is less suitable.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a cohort in Asymptomatic high-grade carotid artery stenosis (n=889). Transcarotid artery revascularization (TCAR) vs. Carotid endarterectomy (CEA) was evaluated on Composite of TIA, stroke, MI, or death (aHR 1.57, 95% CI 1.11-2.24). TCAR had 0% 30-day stroke, TIA, MI, or death, and after matching showed no significant difference vs CEA in mortality, composite events, or restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: